Table 1.

Clinical and virological characteristics of patients with a history of HCC treatments before and after DAA therapy

Age (years)	71.7 ± 8.0
Sex (male/female)	126/73
Body mass index (kg/m2)	23.2 ± 3.2
White blood cell count (/μL)	4295 ± 1370
Platelet count (× 104/μL)	11.9 ± 8.0
ALT (U/L)	47.1 ± 30.3
AST (U/L)	52.3 ± 26.7
Total bilirubin (mg/dL)	0.8 ± 0.4
Albumin (g/dL)	3.8 ± 0.4
Prothrombin time (%)	82.9 ± 15.4
AFP (ng/mL)	20.8 ± 53.0
eGFR (mL/min/1.73 m2)	67.7 ± 20.3
Total cholesterol (mg/dL)	151.5 ± 27.9
Diabetes mellitus (no/yes)	149/49
Alcohol (none/drinking/unknown)	152/22/25
FIB-4 index	5.8 ± 3.7
APRI	1.6 ± 1.5
HCV RNA (log copies/mL)	5.8 ± 0.7
Post-treatment ALT (U/L)	22.8 ± 22.4
Post-treatment AST (U/L)	29.4 ± 16.4
Post-treatment total bilirubin (mg/dL)	0.8 ± 0.4
Post-treatment albumin (g/dL)	3.9 ± 0.4
Post-treatment prothrombin time (%)	83.5 ± 15.8
Post-treatment AFP (ng/mL)	8.2 ± 10.5
Post-treatment eGFR (mL/min/1.73 m2)	65.6 ± 19.3
SVR/no SVR	184/15
Child-Pugh class (A/B/C/unknown)	161/26/1/11
BCLC stage (0/A/B/C/D)	81/49/31/35/3
Latest HCC treatment (RFA/surgical resection)	178/21
Number of months from HCC treatment to DAA therapy initiation	20 ± 26
Number of curative treatments for HCC	1.1 ± 1.5
DAA therapy (SOF + LDV/SOF + RBV/ASV + DCV/OBV + PTV + r/EBR + GZR)	90/26/53/18/12

Data are expressed as means ± standard deviation

ALT alanine aminotransferase; AST aspartate aminotransferase; AFP α-fetoprotein; eGFR estimated glomerular filtration rate; FIB-4 fibrosis-4; APRI AST to platelet ratio index; HCV hepatitis C virus; RNA ribonucleic acid; SVR sustained virological response; BCLC Barcelona Clinic Liver Cancer; RFA radiofrequency ablation; DAA direct-acting antiviral; SOF sofosbuvir; LDV ledipasvir; RBV ribavirin; ASV asunaprevir; DCV daclatasvir; OBV ombitasvir; PTV paritaprevir; r ritonavir; EBR elbasvir; GZR grazoprevir